Fluid overload is a key cause of condition deterioration and hospital readmission in patients with heart failure. There is a significant need for improved fluid monitoring in this chronic condition to allow for early detection, intervention, reduced hospitalisation rates and improved patient outcomes.
Cardia includes a handheld device that measures distension and pulsation at the jugular vein and, when placed on the chest, listens to heart and lung sounds. It also inludes an ankle-worn bioimpedence device to measure peripheral fluid levels and a monitoring and wellness app.
Heart failure affects at least 26 million people worldwide and is the primary reason for hospitalisation >65 years of age. Half of heart failure patients are readmitted to hospital in the first six months after discharge. The global chronic heart failure treatment devices market alone was estimated to be at $10 billion (USD) in 2015, and was projected to reach $14.8 billion (USD) by 2022.